Chronic kidney disease after lung transplantation in a changing era

Transplant Rev (Orlando). 2022 Dec;36(4):100727. doi: 10.1016/j.trre.2022.100727. Epub 2022 Sep 15.

Abstract

Lung transplant (LTx) physicians are responsible for highly complex post-LTx care, including monitoring of kidney function and responding to kidney function loss. Better survival of the LTx population and changing patient characteristics, including older age and increased comorbidity, result in growing numbers of LTx patients with chronic kidney disease (CKD). CKD after LTx is correlated with worse survival, decreased quality of life and high costs. Challenges lie in different aspects of post-LTx renal care. First, serum creatinine form the basis for estimating renal function, under the assumption that patients have stable muscle mass. Low or changes in muscle mass is frequent in the LTx population and may lead to misclassification of CKD. Second, standardizing post-LTx monitoring of kidney function and renal care might contribute to slow down CKD progression. Third, new treatment options for CKD risk factors, such as diabetes mellitus, proteinuria and heart failure, have entered clinical practice. These new treatments have not been studied in LTx yet but are of interest for future use. In this review we will address the difficult aspects of post-LTx renal care and evaluate new and promising future approaches to slow down CKD progression.

Keywords: Cardiovascular disease; Chronic kidney disease; Cystatin C; Glucagon-like peptide-1 (GLP1) agonists; Lung transplantation; Sodium-glucose co-transporter-2 (SGLT2) inhibitors.

Publication types

  • Review

MeSH terms

  • Diabetes Mellitus*
  • Humans
  • Lung Transplantation* / adverse effects
  • Quality of Life
  • Renal Insufficiency, Chronic* / surgery